Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology's CMO, Dr. Charlie Morris
Source: Cell & Gene
Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.
This website uses cookies to ensure you get the best experience on our website. Learn more